Christianne Bourlon1, Dennis Lacayo-Leñero2, Sergio I Inclán-Alarcón2, Roberta Demichelis-Gómez2. 1. Leukemia Clinic, Department of Hematology and Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Avenida Vasco de Quiroga No. 15, Colonia Belisario Domínguez Sección XVI, Delegación Tlalpan, 14080, Mexico City, CP, Mexico. chrisbourlon@hotmail.com. 2. Leukemia Clinic, Department of Hematology and Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Avenida Vasco de Quiroga No. 15, Colonia Belisario Domínguez Sección XVI, Delegación Tlalpan, 14080, Mexico City, CP, Mexico.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to discuss the potential role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for Philadelphia-negative (Ph-) adult acute lymphoblastic leukemia (ALL) in first complete remission (CR1) in the era of minimal residual disease (MRD). RECENT FINDINGS: Allo-HSCT continues to have a role in the therapy of a selected group of high-risk adult patients with ALL in CR1. Although the clinical significance of MRD has been studied less extensively in adults with ALL than in children, recent studies support its role as the strongest prognostic factor that can identify patients that are unlikely to be cured by standard chemotherapy and benefit from undergoing allo-HSCT. In addition, MRD status both pre- and post-HSCT has been found to correlate directly with the risk of relapse. Currently, the clinical challenge consists on applying MRD and molecular failure to integrate novel agents and immunotherapy to lower MRD before allo-HSCT and to modulate the graft versus leukemia (GVL) effect after transplant.
PURPOSE OF REVIEW: The purpose of this review is to discuss the potential role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for Philadelphia-negative (Ph-) adult acute lymphoblastic leukemia (ALL) in first complete remission (CR1) in the era of minimal residual disease (MRD). RECENT FINDINGS: Allo-HSCT continues to have a role in the therapy of a selected group of high-risk adult patients with ALL in CR1. Although the clinical significance of MRD has been studied less extensively in adults with ALL than in children, recent studies support its role as the strongest prognostic factor that can identify patients that are unlikely to be cured by standard chemotherapy and benefit from undergoing allo-HSCT. In addition, MRD status both pre- and post-HSCT has been found to correlate directly with the risk of relapse. Currently, the clinical challenge consists on applying MRD and molecular failure to integrate novel agents and immunotherapy to lower MRD before allo-HSCT and to modulate the graft versus leukemia (GVL) effect after transplant.
Entities:
Keywords:
Acute lymphoblastic leukemia; Adult patients; Early consolidation MRD status; Graft versus host disease; Graft versus leukemia; Hematopoietic stem cell transplantation; Intensified therapy; MRD techniques; Minimal residual disease; Philadelphia negative ALL
Authors: Joaquín Sánchez; Josefina Serrano; Pedro Gómez; Francisco Martínez; Carmen Martín; Luis Madero; Concepción Herrera; J Manuel García; Javier Casaño; Antonio Torres Journal: Br J Haematol Date: 2002-03 Impact factor: 6.998
Authors: F Locatelli; M Zecca; R Rondelli; F Bonetti; G Dini; A Prete; C Messina; C Uderzo; M Ripaldi; F Porta; G Giorgiani; E Giraldi; A Pession Journal: Blood Date: 2000-03-01 Impact factor: 22.113
Authors: Orietta Spinelli; Barbara Peruta; Manuela Tosi; Vittoria Guerini; Anna Salvi; Maria Cristina Zanotti; Elena Oldani; Anna Grassi; Tamara Intermesoli; Caterina Micò; Giuseppe Rossi; Pietro Fabris; Giorgio Lambertenghi-Deliliers; Emanuele Angelucci; Tiziano Barbui; Renato Bassan; Alessandro Rambaldi Journal: Haematologica Date: 2007-05 Impact factor: 9.941
Authors: J Sanchez-Garcia; J Serrano; J Serrano-Lopez; P Gomez-Garcia; F Martinez; J M Garcia-Castellano; R Rojas; C Martin; A Rodriguez-Villa; J R Molina-Hurtado; M A Alvarez; J Casaño; A Torres-Gomez Journal: Bone Marrow Transplant Date: 2012-07-30 Impact factor: 5.483
Authors: R Bassan; O Spinelli; E Oldani; T Intermesoli; M Tosi; B Peruta; E Borlenghi; E M Pogliani; E Di Bona; V Cassibba; A M Scattolin; C Romani; F Ciceri; A Cortelezzi; G Gianfaldoni; D Mattei; E Audisio; A Rambaldi Journal: Blood Cancer J Date: 2014-07-11 Impact factor: 11.037
Authors: Paola Ghione; Alison J Moskowitz; Nadia E K De Paola; Steven M Horwitz; Marco Ruella Journal: Curr Hematol Malig Rep Date: 2018-12 Impact factor: 3.952
Authors: C Greil; M Engelhardt; G Ihorst; J Duque-Afonso; K Shoumariyeh; H Bertz; R Marks; R Zeiser; J Duyster; J Finke; R Wäsch Journal: Bone Marrow Transplant Date: 2020-10-31 Impact factor: 5.483